drugset / Trial / NCT05260671
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
NaSingle-groupOpen-labelTreatment
Summary
This trial is a multicenter, prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of Penpulimab injection combined with cetuximab in the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Timeline
- Start
- 2022-01-25
- Primary completion
- 2024-12-25
- Completion
- 2026-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |